This conference call transcript was computer generated and almost certianly contains errors. This transcript is provided for information purposes only.EarningsCall, LLC makes no representation about the accuracy of the aforementioned transcript, and you are cautioned not to place undue reliance on the information provided by the transcript.
10/26/2023
David
CEO
but also we continue to see opportunities in our portfolio. As you know, we had multiple readouts this quarter, you know, LPA being one of those, as well as additional indications for Opdivo, and we had first-line commands. But as we step back and what we shared at R&D Day, we see opportunities to continue to accelerate in our R&D pipeline. So that's why we revised our guidance to incorporate the dilution from Mirati, but as well as the investments that we're making in a new product portfolio and the R&D portfolio.
Keith
Executive
Thanks, David. Keith, can we go to the next question, please?
Operator
Operator
Yes, and that comes from Seamus Fernandez with Guggenheim.
You're reading a preview of the BMY Q3 2023 earnings call.
Free account.
Disclaimer